CMT2L型转基因小鼠的基因鉴定与行为学分析
摘要
腓骨肌萎缩症(Charcot-Marie-Tooth disease, CMT)具有高度的临床和遗传异质性,是最常见遗传性的周围神经病,临床上以肢体远端肌肉的进行性对称性的无力、萎缩、感觉减退和腱反射减弱等为主要特征,发病率约为1/2500。根据病理学和电生理特点,临床上依据其病理和电生理特点可分为两型：脱髓鞘型(CMT1型)和轴突型(CMT2型),根据遗传方式不同,腓骨肌萎缩症可分为常染色体隐性遗传(AR)、常染色体显性遗传(AD)、和X连锁遗传(XD/XR)。
研究表明,腓骨肌萎缩症各亚型致病基因的具体分子发病机制并不完全相同,可能是通过致病基因的功能丧失、功能获得、剂量效应、显性-负性作用而致病。本实验采取基因鉴定和行为学分析方法验证该携带人类突变的pCAGGS-HA-K141NHSPB8转基因小鼠。基因鉴定结果表明F3代有9只pCAGGS-HA-K141NHSPB8转基因小鼠和9只pCAGGS-HA-wtHSPB8转基因小鼠。行为学方法包括足迹实验、固定棒试验、旋转棒试验、痛阈实验。足迹实验方差分析结果：MT(突变组)、WT(过表达组)、NT(正常组)三组F2,F3代足迹分析足印长、步长随机区组设计资料方差分析多重比较p<0.05,有统计学意义；固定棒试验结果MT、WT小鼠运动协调能力较NT小鼠较运动协调能力降低；MT F3代在转棒上停留时间明显少于NT和WT的F3代在转棒上停留时间,p<0.05。旋转棒试验结果表明pCAGGS-HA-K141NHSPB8突变小鼠下肢周围神经运动功能受损；足底电击痛阈实验统计学方差分析,p>0.05, MT, WT, NT三种基因型的小鼠之间的痛阈值无明显差异,表明pCAGGS-HA-K141NHSPB8突变小鼠下肢周围感觉神经无明显受累。
Charcot-Marie-Tooth disease (CMT), also known as hereditary motor and sensory neuropathy (HMSN), is the most common hereditary peripheral neuropathy with highly clinical and genetic heterogeneity. CMT is characterized by progressive and symmetric distal muscle atrophy, weakness, hyporeflexia and hypoesthesia in distal limbs. The incidence of CMT is about 1/2500. According to the electrophysiological and histopathological criteria, CMT can be divided into two forms:the demyelinating form (CMT1) and the axonal form (CMT2). Several modes of inheritance have been described in CMT, including autosomal dominant (AD), autosomal recessive (AR) and X-linked dominant or recessive (XD/XR).
Although many mutations of a number of genes have been associated with CMT, the disease mechanisms caused by each gene may be different. The main mechanisms include dosage effect, loss of function, gain of function or dominant-negative effect.This experiment wo breed the transgenic mice which carry mutation of human pCAGGS-HA-K141N HSPB8 gene by behavior analysis and gene identification.we gain nine pCAGGS-HA-K141N HSPB8 and nine pCAGGS -HA-WT HSPB8 gene transgenic mouse. The behavior tests contain footprinting test, bar test, rotarod test and foot sole lancinating pain threshold test. The result of footprinting test analysis of variance:the randomized block design material anova multiple comparison of the F2 and F3 transgenic mice mutations group(MT),over expressing group(WT)and normal group(NT):p<0.05, have statistical significance. The result of bar test analysis of variance:the motor coordination ability of transgenic mice mutations group and over expressing group are less than normal group; The time of F3 transgenic mice mutations group in fixed stick are less than over expressing group (WT) and normal group(NT):p<0.05, have statistical significance. The result of Rotating experiment:the lower extremity peripheral nerve of transgenic mice mutations group have damaged in movement function. The result of foot sole lancinating pain threshold experiment analysis of variance:p>0.05, have no statistical significance.
研究表明,腓骨肌萎缩症各亚型致病基因的具体分子发病机制并不完全相同,可能是通过致病基因的功能丧失、功能获得、剂量效应、显性-负性作用而致病。本实验采取基因鉴定和行为学分析方法验证该携带人类突变的pCAGGS-HA-K141NHSPB8转基因小鼠。基因鉴定结果表明F3代有9只pCAGGS-HA-K141NHSPB8转基因小鼠和9只pCAGGS-HA-wtHSPB8转基因小鼠。行为学方法包括足迹实验、固定棒试验、旋转棒试验、痛阈实验。足迹实验方差分析结果：MT(突变组)、WT(过表达组)、NT(正常组)三组F2,F3代足迹分析足印长、步长随机区组设计资料方差分析多重比较p<0.05,有统计学意义；固定棒试验结果MT、WT小鼠运动协调能力较NT小鼠较运动协调能力降低；MT F3代在转棒上停留时间明显少于NT和WT的F3代在转棒上停留时间,p<0.05。旋转棒试验结果表明pCAGGS-HA-K141NHSPB8突变小鼠下肢周围神经运动功能受损；足底电击痛阈实验统计学方差分析,p>0.05, MT, WT, NT三种基因型的小鼠之间的痛阈值无明显差异,表明pCAGGS-HA-K141NHSPB8突变小鼠下肢周围感觉神经无明显受累。
Charcot-Marie-Tooth disease (CMT), also known as hereditary motor and sensory neuropathy (HMSN), is the most common hereditary peripheral neuropathy with highly clinical and genetic heterogeneity. CMT is characterized by progressive and symmetric distal muscle atrophy, weakness, hyporeflexia and hypoesthesia in distal limbs. The incidence of CMT is about 1/2500. According to the electrophysiological and histopathological criteria, CMT can be divided into two forms:the demyelinating form (CMT1) and the axonal form (CMT2). Several modes of inheritance have been described in CMT, including autosomal dominant (AD), autosomal recessive (AR) and X-linked dominant or recessive (XD/XR).
Although many mutations of a number of genes have been associated with CMT, the disease mechanisms caused by each gene may be different. The main mechanisms include dosage effect, loss of function, gain of function or dominant-negative effect.This experiment wo breed the transgenic mice which carry mutation of human pCAGGS-HA-K141N HSPB8 gene by behavior analysis and gene identification.we gain nine pCAGGS-HA-K141N HSPB8 and nine pCAGGS -HA-WT HSPB8 gene transgenic mouse. The behavior tests contain footprinting test, bar test, rotarod test and foot sole lancinating pain threshold test. The result of footprinting test analysis of variance:the randomized block design material anova multiple comparison of the F2 and F3 transgenic mice mutations group(MT),over expressing group(WT)and normal group(NT):p<0.05, have statistical significance. The result of bar test analysis of variance:the motor coordination ability of transgenic mice mutations group and over expressing group are less than normal group; The time of F3 transgenic mice mutations group in fixed stick are less than over expressing group (WT) and normal group(NT):p<0.05, have statistical significance. The result of Rotating experiment:the lower extremity peripheral nerve of transgenic mice mutations group have damaged in movement function. The result of foot sole lancinating pain threshold experiment analysis of variance:p>0.05, have no statistical significance.
引文
[1]Hogan B,Beddington R,Costantini F,et al. Manipulating the Mouse Embryo:A Laboratory Manual. New York, Cold Spring Harbor Laboratory Press, 1994,117-119.
[2]Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathy types Ⅰ and Ⅱ. Brain,1980,103(2):259-280.
[3]Davis CJ, Bradley WG, Madrid R. The peroneal muscular atrophy syndrome: clinical, genetic, electrophysiological and nerve biopsy studies. I. Clinical, genetic and electrophysiological findings and classification. J Hum Genet,1978, 26(4):311-349.
[4]Matsunami N, Smith B, Ballard L, et al. Peripheral myelin protein-22 gene maps in the duplication in chromosome 17p11.2 associated with Charcot-Marie-Tooth 1A. Nat Genet,1992,1(3):176-179.
[5]Street VA, Bennett CL, Goldy JD, et al. Mutation of a putative protein degradation gene LITAF/SIMPLE in Charcot-Marie-Tooth disease 1C. Neurology,2003,60(1):22-26.
[6]Chapon F, Latour P, Diraison P, et al. Axonal phenotype of Charcot-Marie-Tooth disease associated with a mutation in the myelin protein zero gene. J Neurol Neurosurg Psychiatry,1999,66(6):779-782.
[7]Bellone E, Di Maria E, Soriani S, et al. A novel mutation (D305V) in the early growth response 2 gene is associated with severe Charcot-Marie-Tooth type 1 disease. Hum Mutat,1999,14(4):353-354.
[8]Hayasaka K, Takada G, Ionasescu VV. Mutation of the myelin P0 gene in Charcot-Marie-Tooth neuropathy type 1B. Hum Mol Genet,1993,2(9):1369-1372.
[9]Rogers T, Chandler D, Angelicheva D, et al. A novel locus for autosomal recessive peripheral neuropathy in the EGR2 region on 10q23. Am J Hum Genet,2000,67(3):664-671.
[10]Kwon JM, Elliot JL, Yee W, et al. Assignment of a second locus for Charcot-Marie-Tooth type Ⅱ locus to chromosome 3q. Am J HumGenet.1995, 57(4):853-858.
[11]Zhao C, Takita J, Tanaka Y, et al. Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1B. Cell,2001,105(5):587-597.
[12]Sambuughin N, Sivakumar K, Selenge B, et al. Autosomal dominant distal spinal muscular atrophy type V (dSMA2V) and Charcot-Marie-Tooth disease type 2D (CMT2D) segregate within a single large kindred and map to a refined region on chromosome 7p15. J Neurol Sci,1998,161(1):23-28.
[13]Takashima H, Nakagawa M, Suehara M, et al. Gene for hereditary motor and sensory neuropathy (proximal dominant form) mapped to 3q13.1. Neuromuscul Disord,1999,9(6-7):368-371.
[14]Ionasescu V, Searby C, Sheffield VC, et al. Autosomal dominant Charcot-Marie- Tooth axonal neuropathy mapped on chromosome 7p (CMT2D). Hum Mol Genet,1996,5(9):1373-1375.
[15]De Jonghe P, Mersivanova I, Nelis E, et al. Further evidence that neurofilament light chain gene mutations can cause Charcot-Marie-Tooth disease type 2E. Ann Neurol,2001,49(2):245-249.
[16]Berger P, Young P, Suter U. Molecular cell biology of Charcot-Marie-Tooth disease. Neurogenetics,2002,4(1):1-15.
[17]Kalaydjieva L, Gresham D, Gooding R, et al. N-myc downstream regulated gene 1 is mutated in hereditary motor and sensory neuropathy Lom. Am J Hum Genet,2000,67(1):47-58.
[18]Jordanova A, De Jonghe P, Boerkoel CF, et al. Mutations in the neurofilament light chain gene (NEFL) cause early onset severe Charcot-Marie-Tooth disease. Brain,2003,126(3):590-597.
[19]Jordanova A, Irobi J, Thomas FP, et al. Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy. Nature Genet,2006,38:197-202.
[20]Nelis E, Berciano J, Verpoorten N, et al. Autosomal dominant axonal Charcot-Marie-Tooth disease type 2 (CMT2G) maps to chromosome 12q12-q13. 3. J Med Genet,2004,41(3):193-197.
[21]Tang BS, Luo W, Xia K, et al. A new locus for autosomal dominant Charcot-Marie-Tooth disease type 2 (CMT2L) maps to chromosome 12q24. Hum Genet.2004,114(6):527-533.
[22]Tang BS, Zhao GH, Luo W, et al. Small heat-shock protein 22 mutated in autosomal dominant Charcot-Marie-Tooth disease type 2L. Hum Genet. 2005,116(3):222-224.
[23]Hahn AF, Brown WF, Koopman WJ, et al. X-linked dominant hereditary motor and sensory neuropathy. Brain,1990,113(5):1511-1525.
[24]Nelis E, Erdem S, Van Den Bergh PY, et al. Mutations in GDAP1:autosomal recessive CMT with demyelination and axonopathy. Neurology,2002,59(12): 1865-1872.
[25]Baxter RV, Othmane BK, Rochelle JM, et al. Ganglioside induced differentiation associated protein1 is mutant in Charcot-Marie-Tooth disease type 4A/8q21. Nat Genet,2002,30(1):21-22.
[26]Guilbot A, Williams A, Ravise N, et al. A mutation in periaxin is responsible for CMT4F, an autosomal recessive form of Charcot-Marie-Tooth disease. Hum Mol Genet,2001,10(4):415-421.
[27]Georgiou DM, Zidar J, Korosec M, et al. A novel NF-L mutation Pro22Seris associated with CMT2 in a large slovenian family. Neurogenetics,2002,4(2): 93-96.
[28]Bolino A, Brancolini V, Bono F, et al. Localization of a gene responsible for autosomal recessive demyelinating neuropathy with focally folded myelin sheaths to chromosome 11 q23 by homozygosity mapping and haplotype sharing. Hum Mol Genet,1996,5(7):1051-1054.
[29]Kalaydjieva L, Nikolova A, Turnev I, et al. Hereditary motor and sensory neuropathy LOM, a novel demyelinating neuropathy associated with deafness in gypsies. Clinical, electrophysiological and nerve biopsy findings. Brain,1998, 121(pt 3):399-408.
[30]Bolino A, Muglia M, Conforti F et al. Charcot-Marie- Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2. Nature Genet, 2000,25(1):17-19.
[31]Zuchner S, Noureddine M, Kennerson M, et al. Mutations in the pleckstrin homology domain of dynamin 2 cause dominant intermediate Charcot-Marie-Tooth disease. Nature Genet,2005,37(3):289-294.
[32]Boerkoel CF, Takashima H, Stankiewicz P et al. Periaxin mutations cause recessive Dejerine-Sottas neuropathy. Hum Genet,2001,68(2):325-333.
[33]Antonellis A, Ellsworth, RE, Sambuughin N et al. Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type Ⅴ. Hum Genet,2003,72(5):1293-1295.
[34]Stock AD, Spallone PA, Dennis TR et al. Heat shock protein 27 gene chromosomal and molecular location and relationship to Williams syndrome. Med Genet,2003,120(3):320-325.
[35]De Sandre-Giovannoli A, Chaouch M, Kozlov S, et al. Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse. Hum Genet,2002,70(3):726-736.
[36]Zuchner S, Mersiyanova IV, Muglia M et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nature Genet,2004,36(5):449-451.
[37]Lupski JR, Montes de Oca-Luna R, Slaugenhaupt S, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell,1991,66(2): 219-232.
[38]Taylor V, Welcher AA, Program AE, et al. Epithelial membrane protein 21, peripheral myelin protein 22, and lens membrane protein 20 define a novel gene family. J Biol Chem,1995,270(48):28824-28833.
[39]Baechner D, Liehr T, Hameister H, et al. Widespread expression of the peripheral myelin protein22 gene (PMP22) in neural and nonneural tissues during murine development. J Neurosci Res,1995,42(6):733-741.
[40]Parmantier E, Cabon F, Braun C, et al. Peripheral myelin protein 22 is expressed in rat and mouse brain and spinal cord motoneurons, Eur J Neurosci, 1995,7(5):1080-1088.
[41]Hayasaka K, Himoro M, Sawaishi Y, et al. De novo mutation of the myelin P(0) gene in Dejerine-Sottas disease (hereditary motor and sensory neuropathy type Ⅲ). Nat Genet,1993,5(3):266-268.
[42]Auer-Grumbach M, Strasser-Fuchs S, Robl T, et al. Late onset Charcot-Marie-Tooth 2 syndrome caused by two novel mutations in the MPZ gene. Neurology,2003,63(1):1435-1437.
[43]Seeman P, Mazanec R, Huehne K, et al. Hearing loss as the first feature of late-onset axonal CMT disease due to a novel P0 mutation. Neurology,2004, 63(4):733-735.
[44]Myokai F, Takashiba S, Lebo R, et al. A novel lipopolysaceharide-induced transcription factor regulating tumor necrosis factor alpha gene expression: molecular cloning, sequencing, characterization, and chromosomal assignment. Proc Nat Acad Sci USA,1999,96(8):4518-4523.
[45]Agarajan R, Svaren J, Le N, et al. EGR2 mutations in inherited neuropathies dominant negatively inhibit myelin gene expression. Neuron,2001,30(2): 355-368.
[46]Warner LE, Mancias P, Butler IJ, et al. Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet,1998, 18(4):382-384.
[47]Mersiyanova IV, Perepelov AV, Polyakov AV, et al. A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. Am. J. Hum. Genet,2000,67(1):37-46.
[48]Raul Perez-Olle, Conrad L. Leung and Ronald K. H, Liem. Effects of Charcot-Marie-Tooth-linked mutations of the neurofilament light subunit on intermediate filament formation. J Cell Sci,2002,115(24):4937-4946.
[49]Cuesta A, Pedrola L, Sevilla T, et al. The gene encoding ganglioside-induced differentiation-associated protein 1 is mutated in axonal Charcot-Marie-Tooth type 4A disease. Nat Genet,2002,30(1):22-25.
[50]Boerkoel CF, Takashima H, Nakagawa M. CMT4A:identification of a hispanic GDAP1 founder mutation. Ann Neurol,2003,53(3):400-405.
[51]Previtali SC, Zerega B, Sherman DL, et al. Myotubularin-related protein phosphatase and neurofilament light chain protein, both mutated in CMT neuropathies, interact in peripheral nerve. Hum Mol Genet,2003,12(14): 1713-1723.
[52]Bolino A, Bolis A, Previtali SC, et al. Disruption of Mtmr2 produces CMT4B1-like neuropathy with myelin outfolding and impaired spermatogenesis. Cell Biol,2004,167(4):711-721.
[53]Senderek J, Bergmann C, Weber S, et al. Mutation of the SBF2 gene, encoding a novel member of the myotubularin family, in Charcot-Marie-Tooth neuropathy type 4B2/11p15. Hum Mol Genet,2003,12(3):349-356.
[54]Azzedine H, Bolino A, Taieb T. et al. Mutations in MTMR13, a new pseudophosphatase homologue of MTMR2 and Sbfl, in two families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease associated with early-onset glaucoma. Am J Hum Genet,2003,72(5): 1141-1153.
[55]Senderek J, Bergmann C, Stendel C, et al. Mutations in a gene encoding a novel SH3/TPR domain protein cause autosomal recessive Charcot-Marie-Tooth type 4C neuropathy. Am J Hum Genet,2003,73(5):1106-1119.
[56]Hunter M, Bernard R, Freitas E, et al. Mutation screening of the N-myc downstream-regulated gene 1 (NDRG1) in patients with Charcot-Marie-Tooth disease. Hum Mutat.2003,22(2):129-135.
[57]Boerkoel CF, Takashima H, Stankiewicz P, et al. Periaxin mutations cause recessive Dejerine-Sottas neuropathy. Am J Hum Genet,2001,68(2):325-333.
[58]Kim HJ,Sohn KM,Shy ME,et al. Mutations in PRPS1, which encodes the phosphoribosyl pyrophosphate synthetase enzyme critical for nucleotide biosynthesis, cause hereditary peripheral neuropathy with hearing loss and optic neuropathy (CMT5X). Am J Hum Genet.2007,81(3):552-558.
[59]张付峰,HSP22转基因小鼠模型的建立,[博士学位论文],长沙：中南大学,2008。
[60]Irobi J, Van Impe K, Seeman P, et al. Hot-spot residue in small heat-shock protein 22 causes distal motor neuropathy. Nat Genet.2004,36(6):597-601.
[61]Sun Y, MacRae TH. The small heat shock proteins and their role in human disease. FEBS J,2005,272(11):2613-2627.
[62]Arrigo A, Simon S, Gibert B, et al. Hsp27 (HspB1) and alphaB-crystallin (HspB5) as therapeutic targets. FEBS Lett,2007,581(19):3665-3674.
[63]Launay N, Goudeau B, Kato K, et al. Cell signaling pathways to alphaB-crystallin following stresses of the cytoskeleton. Exp Cell Res.2006, 312(18):3570-3584.
[64]Theriault JR, Lambert H, Chavez-Zobel, et al. Essential role of the NH2-terminal WD/EPF motif in the phosphorylation-activated protective function of mammalian Hsp27. J Biol Chem.2004,279(22):23463-23471.
[65]Sereda MW, Griffiths I, Puhlhofer A, et al. A transgenic rat model of Charcot-Marie-Tooth disease. Neuron,1996,16(5):1049-1060.
[66]Suter U, Welcher AA, Ozcelik T, et al. Trembler mouse carries a point mutation in a myelin gene. Nature,1992,356(6366):241-244.
[67]Huxley C, Passage E, Manson A, et al. Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. Hum Mol Genet,1996,5(5):563-569.
[68]Huxley C, Passage E, Robertson AM, et al. Correlation between varying levels of PMP22 expression and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice. Hum Mol Genet,1998,7(3):449-458.
[69]Magyar JP, Martini R, Ruelicke T, et al. Impaired differentiation of Schwann cells in transgenic mice with increased PMP22 gene dosage. J Neurosci,1996, 16(17):5351-5360.
[70]Robertson AM, Perea J, McGuigan A, et al. Comparison of a new pmp22 transgenic mouse line with other mouse models and human patients with CMT1A. J Anat,2002,200(4):377-390.
[71]Suter U, Moskow JJ, Welcher AA, et al. A leucine-to-proline mutation in the putative first transmembrane domain of the 22-kDa peripheral myelin protein in the trembler-J mouse. Proc Natl Acad Sci USA,1992,89(10):4382-4386.
[72]Suh JG, Ichihara N, Saigoh K, et al. An in-frame deletion in peripheral myelin protein-22 gene causes hypomyelination and cell death of the Schwann cells in the new Trembler mutant mice. Neuroscience,1997,79(3):735-744.
[73]Isaacs AM, Davies KE, Hunter AJ, et al. Identification of two new Pmp22 mouse mutants using large-scale mutagenesis and a novel rapid mapping strategy. Hum Mol Genet,2000,9(12):1865-1871.
[74]Adlkofer K, Martini R, Aguzzi A, et al. Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat Genet,1995,1(3):274-280.
[75]Adlkofer K, Frei R, Neuberg DH, et al. Heterozygous peripheral myelin protein 22-deficient mice are affected by a progressive demyelinating tomaculous neuropathy. J Neurosci,1997,17(12):4662-4671.
[76]Giese KP, Martini R, Lemke G, et al. Mouse P0 gene disruption leads to hypomyelination, abnormal expression of recognition molecules, and degeneration of myelin and axons. Cell,1992,71(4):565-576.
[77]Wrabetz L, Feltri ML, Quattrini A, et al. P(0) glycoprotein overexpression causes congenital hypomyelination of peripheral nerves. J Cell Biol, 2000,148(5):1021-1034.
[78]Runker AE, Kobsar I, Fink T, et al. Pathology of a mouse mutation in peripheral myelin protein P0 is characteristic of a severe and early onset form of human Charcot-Marie-Tooth type 1B disorder. J Cell Biol,2004,165(4):565-573.
[79]Wrabetz L, D'Antonio M, Pennuto M, et al. Different intracellular pathomechanisms produce diverse myelin protein zero neuropathies in transgenic mice. J Neurosci,2006,26(8):2358-2368.
[80]Anzini P, Neuberg DH, Schachner M, et al. Structural abnormalities and deficient maintenance of peripheral nerve myelin in mice lacking the gap junction protein connexin 32. J Neurosci,1997,17(12):4545-4551.
[81]Scherer SS, Bone LJ, Deschenes SM, et al. The role of the gap junction protein connexin32 in the pathogenesis of X-linked Charcot-Marie-Tooth disease. Novartis Found Symp,1999,219:175-185.
[82]Schneider-Maunoury S, Topilko P, Seitandou T, et al. Disruption of Krox-20 results in alteration of rhombomeres 3 and 5 in the developing hindbrain. Cell, 1993,75(6):1199-1214.
[83]Nagarajan R, Le N, Mahoney H, et al. Deciphering peripheral nerve myelination by using Schwann cell expression profiling. Proc Natl Acad Sci USA,2002, 99(13):8998-9003.
[84]Gillespie CS, Sherman DL, Fleetwood-Walker SM, et al. Peripheral demyelination and neuropathic pain behavior in periaxin-deficient mice. Neuron, 2000,26(2):523-531.
[85]Bolino A, Bolis A, Previtali SC, et al. Disruption of Mtmr2 produces CMT4B1-like neuropathy with myelin outfolding and impaired spermatogenesis. J Cell Biol,2004,167(4):711-721.
[86]Bonneick S, Boentert M, Berger P, et al. An animal model for Charcot-Marie-Tooth disease type 4B1. Hum Mol Genet,2005,14(23):3685-3695.
[87]Zhao C, Takita J, Tanaka Y, et al. Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta. Cell,2001,105(5):587-597.
[88]Lee MK, Marszalek JR, Cleveland DW. A mutant neurofilament subunit causes massive, selective motor neuron death:implications for the pathogenesis of human motor neuron disease. Neuron,1994,13(4):975-988.
[89]De Sandre-Giovannoli A, Chaouch M, Kozlov S, et al. Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse. Am J Hum Genet,2002,70(3):726-736.
[90]Miyazaki J, Takaki S, Araki K, et al. Expression vector system based on the chicken beta-actin promoter directs efficient production of interleukin-5.Gene. 1989,79(2):269-277.
[91]Sereda MW, Meyer zu Horste G, Suter U, et al. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med,2003,9(12):1533-1537.
[92]Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med,2004,10(4):396-401.
[93]Kappe G, Franck E, Verschuure P, et al. The human genome encodes 10 alpha-crystallin-related small heat shock proteins:HspB1-10. Cell Stress Chaperones.2003,8(1):53-61.
[94]Zhu Q, Couillard-Despres S, Julien JP. Delayed maturation of regenerating myelinated axons in mice lacking neurofilaments. Exp Neurol,1997, 148:299-316.
[95]Wilhelmus MM, Boelens WC, Otte-Holler I,et al. Small heat shock protein HSPB8:its distribution in Alzheimer's disease brains and its inhibition of amyloid-beta protein aggregation and cerebrovascular amyloid-beta toxicity. Acta Neuropathol.2006,111 (2):139-149.
[96]Outeiro TF, Klucken J, Strathearn KE, et al. Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. Biochem Biophys Res Commun.2006,351(3):631-638.
[97]Zourlidou A, Gidalevitz T, Kristiansen M, et al. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease:chronic neurodegeneration does not induce Hsp27 activation. Hum Mol Genet.2007,16(9):1078-1090.
[98]Sharp PS, Akbar MT, Bouri S, et al. Protective effects of heat shock protein 27 in a model of ALS occur in the early stages of disease progression. Neurobiol Dis.2008,30(1):42-55.
[99]Wang J, Martin E. Gonzales V, et al. Differential regulation of small heat shock proteins in transgenic mouse models of neurodegenerative diseases. Neurobiol Aging.2008,29(4):586-597.
[1]Raeymaekers P, Immerman V, De Jonghe P, et al. Localization of the mutation in an extended family with Charcot-Marie-Tooth neuropathy (HMSN I). Am J Hum Genet,1989,45(6):953-958.
[2]Boerkoel CF, Takashima H, Stankiewicz P, et al. Periaxin mutations cause recessive Dejerine-Sottas neuropathy. Am J Hum Genet,2001,68(2):325-333.
[3]Suter U, Moskow JJ, Welcher AA, et al. A leucine-to-proline mutation in the putative first transmembrane domain of the 22-kDa peripheral myelin protein in the trembler-J mouse. Proc Natl Acad Sci USA,1992,89(10):4382-4386.
[4]Matsunami N, Smith B, Ballard L, et al. Peripheral myelin protein-22 gene maps in the duplication in chromosome 17p11.2 associated with Charcot-Marie-Tooth 1A. Nat Genet,1992,1(3):176-179.
[5]Sereda MW, Griffiths I, Puhlhofer A, et al. A transgenic rat model of Charcot-Marie-Tooth disease. Neuron,1996,16(5):1049-1060.
[6]Sereda MW, Meyer zu Horste G, Suter U, et al. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med,2003,9(12):1533-1537.
[7]Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med,2004,10(4):396-401.
[8]Huxley C, Passage E, Manson A, et al. Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. Hum Mol Genet,1996,5(5):563-569.
[9]Podratz JL, Rodriguez E, Windebank AJ. Role of the extracellular matrix in myelination of peripheral nerve. Glia,2001,35(1):35-40.
[10]Podratz JL, Rodriguez EH, Windebank AJ. Antioxidants are necessary for myelination of dorsal root ganglion neurons, in vitro. Glia,2004,45(1):54-58.。
[11]Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med,2004,10(4):396-401.
[12]Robertson A, Huxley C. Transgenic models of inherited neuropathy. In:Dyck PJ, Thomas PK, editors. Peripheral neuropathy.4th ed. vol.2. Amsterdam:Elsevier Saunders; 2005. pp.1561-1583.A careful review of animal models of inherited neuropathies caused by mutations in myelin proteins.
[13]Wrabetz L, Feltri ML, Suter U. Models of Charcot-Marie-Tooth disease. In:Lazzarini RA, editor. Myelin biology and disorders. Vol.2. Amsterdam:Elsevier Academy; 2004. pp.1143-1168.
[14]Huxley C, Passage E, Robertson AM, et al. Correlation between varying levels of PMP22 expression and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice. Hum Mol Genet,1998,7(3):449-458.
[15]Niemann S, Sereda MW, Suter U, et al. Uncoupling of myelin assembly and Schwann cell differentiation by transgenic overexpression of peripheral myelin protein 22. J Neurosci,2000,20(11):4120-4128.
[16]Robaglia-Schlupp A, Pizant J, Norreel JC, et al. PMP22 overexpression causes dysmyelination in mice. Brain,2002,125(10):2213-2221.
[17]Sereda MW, Meyer zu Horste G, Suter U, et al. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med,2003,9(12):1533-1537.
[18]Adlkofer K, Martini R, Aguzzi A, et al. Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat Genet,1995, 1(3):274-280.
[2]Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathy types Ⅰ and Ⅱ. Brain,1980,103(2):259-280.
[3]Davis CJ, Bradley WG, Madrid R. The peroneal muscular atrophy syndrome: clinical, genetic, electrophysiological and nerve biopsy studies. I. Clinical, genetic and electrophysiological findings and classification. J Hum Genet,1978, 26(4):311-349.
[4]Matsunami N, Smith B, Ballard L, et al. Peripheral myelin protein-22 gene maps in the duplication in chromosome 17p11.2 associated with Charcot-Marie-Tooth 1A. Nat Genet,1992,1(3):176-179.
[5]Street VA, Bennett CL, Goldy JD, et al. Mutation of a putative protein degradation gene LITAF/SIMPLE in Charcot-Marie-Tooth disease 1C. Neurology,2003,60(1):22-26.
[6]Chapon F, Latour P, Diraison P, et al. Axonal phenotype of Charcot-Marie-Tooth disease associated with a mutation in the myelin protein zero gene. J Neurol Neurosurg Psychiatry,1999,66(6):779-782.
[7]Bellone E, Di Maria E, Soriani S, et al. A novel mutation (D305V) in the early growth response 2 gene is associated with severe Charcot-Marie-Tooth type 1 disease. Hum Mutat,1999,14(4):353-354.
[8]Hayasaka K, Takada G, Ionasescu VV. Mutation of the myelin P0 gene in Charcot-Marie-Tooth neuropathy type 1B. Hum Mol Genet,1993,2(9):1369-1372.
[9]Rogers T, Chandler D, Angelicheva D, et al. A novel locus for autosomal recessive peripheral neuropathy in the EGR2 region on 10q23. Am J Hum Genet,2000,67(3):664-671.
[10]Kwon JM, Elliot JL, Yee W, et al. Assignment of a second locus for Charcot-Marie-Tooth type Ⅱ locus to chromosome 3q. Am J HumGenet.1995, 57(4):853-858.
[11]Zhao C, Takita J, Tanaka Y, et al. Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1B. Cell,2001,105(5):587-597.
[12]Sambuughin N, Sivakumar K, Selenge B, et al. Autosomal dominant distal spinal muscular atrophy type V (dSMA2V) and Charcot-Marie-Tooth disease type 2D (CMT2D) segregate within a single large kindred and map to a refined region on chromosome 7p15. J Neurol Sci,1998,161(1):23-28.
[13]Takashima H, Nakagawa M, Suehara M, et al. Gene for hereditary motor and sensory neuropathy (proximal dominant form) mapped to 3q13.1. Neuromuscul Disord,1999,9(6-7):368-371.
[14]Ionasescu V, Searby C, Sheffield VC, et al. Autosomal dominant Charcot-Marie- Tooth axonal neuropathy mapped on chromosome 7p (CMT2D). Hum Mol Genet,1996,5(9):1373-1375.
[15]De Jonghe P, Mersivanova I, Nelis E, et al. Further evidence that neurofilament light chain gene mutations can cause Charcot-Marie-Tooth disease type 2E. Ann Neurol,2001,49(2):245-249.
[16]Berger P, Young P, Suter U. Molecular cell biology of Charcot-Marie-Tooth disease. Neurogenetics,2002,4(1):1-15.
[17]Kalaydjieva L, Gresham D, Gooding R, et al. N-myc downstream regulated gene 1 is mutated in hereditary motor and sensory neuropathy Lom. Am J Hum Genet,2000,67(1):47-58.
[18]Jordanova A, De Jonghe P, Boerkoel CF, et al. Mutations in the neurofilament light chain gene (NEFL) cause early onset severe Charcot-Marie-Tooth disease. Brain,2003,126(3):590-597.
[19]Jordanova A, Irobi J, Thomas FP, et al. Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy. Nature Genet,2006,38:197-202.
[20]Nelis E, Berciano J, Verpoorten N, et al. Autosomal dominant axonal Charcot-Marie-Tooth disease type 2 (CMT2G) maps to chromosome 12q12-q13. 3. J Med Genet,2004,41(3):193-197.
[21]Tang BS, Luo W, Xia K, et al. A new locus for autosomal dominant Charcot-Marie-Tooth disease type 2 (CMT2L) maps to chromosome 12q24. Hum Genet.2004,114(6):527-533.
[22]Tang BS, Zhao GH, Luo W, et al. Small heat-shock protein 22 mutated in autosomal dominant Charcot-Marie-Tooth disease type 2L. Hum Genet. 2005,116(3):222-224.
[23]Hahn AF, Brown WF, Koopman WJ, et al. X-linked dominant hereditary motor and sensory neuropathy. Brain,1990,113(5):1511-1525.
[24]Nelis E, Erdem S, Van Den Bergh PY, et al. Mutations in GDAP1:autosomal recessive CMT with demyelination and axonopathy. Neurology,2002,59(12): 1865-1872.
[25]Baxter RV, Othmane BK, Rochelle JM, et al. Ganglioside induced differentiation associated protein1 is mutant in Charcot-Marie-Tooth disease type 4A/8q21. Nat Genet,2002,30(1):21-22.
[26]Guilbot A, Williams A, Ravise N, et al. A mutation in periaxin is responsible for CMT4F, an autosomal recessive form of Charcot-Marie-Tooth disease. Hum Mol Genet,2001,10(4):415-421.
[27]Georgiou DM, Zidar J, Korosec M, et al. A novel NF-L mutation Pro22Seris associated with CMT2 in a large slovenian family. Neurogenetics,2002,4(2): 93-96.
[28]Bolino A, Brancolini V, Bono F, et al. Localization of a gene responsible for autosomal recessive demyelinating neuropathy with focally folded myelin sheaths to chromosome 11 q23 by homozygosity mapping and haplotype sharing. Hum Mol Genet,1996,5(7):1051-1054.
[29]Kalaydjieva L, Nikolova A, Turnev I, et al. Hereditary motor and sensory neuropathy LOM, a novel demyelinating neuropathy associated with deafness in gypsies. Clinical, electrophysiological and nerve biopsy findings. Brain,1998, 121(pt 3):399-408.
[30]Bolino A, Muglia M, Conforti F et al. Charcot-Marie- Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2. Nature Genet, 2000,25(1):17-19.
[31]Zuchner S, Noureddine M, Kennerson M, et al. Mutations in the pleckstrin homology domain of dynamin 2 cause dominant intermediate Charcot-Marie-Tooth disease. Nature Genet,2005,37(3):289-294.
[32]Boerkoel CF, Takashima H, Stankiewicz P et al. Periaxin mutations cause recessive Dejerine-Sottas neuropathy. Hum Genet,2001,68(2):325-333.
[33]Antonellis A, Ellsworth, RE, Sambuughin N et al. Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type Ⅴ. Hum Genet,2003,72(5):1293-1295.
[34]Stock AD, Spallone PA, Dennis TR et al. Heat shock protein 27 gene chromosomal and molecular location and relationship to Williams syndrome. Med Genet,2003,120(3):320-325.
[35]De Sandre-Giovannoli A, Chaouch M, Kozlov S, et al. Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse. Hum Genet,2002,70(3):726-736.
[36]Zuchner S, Mersiyanova IV, Muglia M et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nature Genet,2004,36(5):449-451.
[37]Lupski JR, Montes de Oca-Luna R, Slaugenhaupt S, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell,1991,66(2): 219-232.
[38]Taylor V, Welcher AA, Program AE, et al. Epithelial membrane protein 21, peripheral myelin protein 22, and lens membrane protein 20 define a novel gene family. J Biol Chem,1995,270(48):28824-28833.
[39]Baechner D, Liehr T, Hameister H, et al. Widespread expression of the peripheral myelin protein22 gene (PMP22) in neural and nonneural tissues during murine development. J Neurosci Res,1995,42(6):733-741.
[40]Parmantier E, Cabon F, Braun C, et al. Peripheral myelin protein 22 is expressed in rat and mouse brain and spinal cord motoneurons, Eur J Neurosci, 1995,7(5):1080-1088.
[41]Hayasaka K, Himoro M, Sawaishi Y, et al. De novo mutation of the myelin P(0) gene in Dejerine-Sottas disease (hereditary motor and sensory neuropathy type Ⅲ). Nat Genet,1993,5(3):266-268.
[42]Auer-Grumbach M, Strasser-Fuchs S, Robl T, et al. Late onset Charcot-Marie-Tooth 2 syndrome caused by two novel mutations in the MPZ gene. Neurology,2003,63(1):1435-1437.
[43]Seeman P, Mazanec R, Huehne K, et al. Hearing loss as the first feature of late-onset axonal CMT disease due to a novel P0 mutation. Neurology,2004, 63(4):733-735.
[44]Myokai F, Takashiba S, Lebo R, et al. A novel lipopolysaceharide-induced transcription factor regulating tumor necrosis factor alpha gene expression: molecular cloning, sequencing, characterization, and chromosomal assignment. Proc Nat Acad Sci USA,1999,96(8):4518-4523.
[45]Agarajan R, Svaren J, Le N, et al. EGR2 mutations in inherited neuropathies dominant negatively inhibit myelin gene expression. Neuron,2001,30(2): 355-368.
[46]Warner LE, Mancias P, Butler IJ, et al. Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet,1998, 18(4):382-384.
[47]Mersiyanova IV, Perepelov AV, Polyakov AV, et al. A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. Am. J. Hum. Genet,2000,67(1):37-46.
[48]Raul Perez-Olle, Conrad L. Leung and Ronald K. H, Liem. Effects of Charcot-Marie-Tooth-linked mutations of the neurofilament light subunit on intermediate filament formation. J Cell Sci,2002,115(24):4937-4946.
[49]Cuesta A, Pedrola L, Sevilla T, et al. The gene encoding ganglioside-induced differentiation-associated protein 1 is mutated in axonal Charcot-Marie-Tooth type 4A disease. Nat Genet,2002,30(1):22-25.
[50]Boerkoel CF, Takashima H, Nakagawa M. CMT4A:identification of a hispanic GDAP1 founder mutation. Ann Neurol,2003,53(3):400-405.
[51]Previtali SC, Zerega B, Sherman DL, et al. Myotubularin-related protein phosphatase and neurofilament light chain protein, both mutated in CMT neuropathies, interact in peripheral nerve. Hum Mol Genet,2003,12(14): 1713-1723.
[52]Bolino A, Bolis A, Previtali SC, et al. Disruption of Mtmr2 produces CMT4B1-like neuropathy with myelin outfolding and impaired spermatogenesis. Cell Biol,2004,167(4):711-721.
[53]Senderek J, Bergmann C, Weber S, et al. Mutation of the SBF2 gene, encoding a novel member of the myotubularin family, in Charcot-Marie-Tooth neuropathy type 4B2/11p15. Hum Mol Genet,2003,12(3):349-356.
[54]Azzedine H, Bolino A, Taieb T. et al. Mutations in MTMR13, a new pseudophosphatase homologue of MTMR2 and Sbfl, in two families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease associated with early-onset glaucoma. Am J Hum Genet,2003,72(5): 1141-1153.
[55]Senderek J, Bergmann C, Stendel C, et al. Mutations in a gene encoding a novel SH3/TPR domain protein cause autosomal recessive Charcot-Marie-Tooth type 4C neuropathy. Am J Hum Genet,2003,73(5):1106-1119.
[56]Hunter M, Bernard R, Freitas E, et al. Mutation screening of the N-myc downstream-regulated gene 1 (NDRG1) in patients with Charcot-Marie-Tooth disease. Hum Mutat.2003,22(2):129-135.
[57]Boerkoel CF, Takashima H, Stankiewicz P, et al. Periaxin mutations cause recessive Dejerine-Sottas neuropathy. Am J Hum Genet,2001,68(2):325-333.
[58]Kim HJ,Sohn KM,Shy ME,et al. Mutations in PRPS1, which encodes the phosphoribosyl pyrophosphate synthetase enzyme critical for nucleotide biosynthesis, cause hereditary peripheral neuropathy with hearing loss and optic neuropathy (CMT5X). Am J Hum Genet.2007,81(3):552-558.
[59]张付峰,HSP22转基因小鼠模型的建立,[博士学位论文],长沙：中南大学,2008。
[60]Irobi J, Van Impe K, Seeman P, et al. Hot-spot residue in small heat-shock protein 22 causes distal motor neuropathy. Nat Genet.2004,36(6):597-601.
[61]Sun Y, MacRae TH. The small heat shock proteins and their role in human disease. FEBS J,2005,272(11):2613-2627.
[62]Arrigo A, Simon S, Gibert B, et al. Hsp27 (HspB1) and alphaB-crystallin (HspB5) as therapeutic targets. FEBS Lett,2007,581(19):3665-3674.
[63]Launay N, Goudeau B, Kato K, et al. Cell signaling pathways to alphaB-crystallin following stresses of the cytoskeleton. Exp Cell Res.2006, 312(18):3570-3584.
[64]Theriault JR, Lambert H, Chavez-Zobel, et al. Essential role of the NH2-terminal WD/EPF motif in the phosphorylation-activated protective function of mammalian Hsp27. J Biol Chem.2004,279(22):23463-23471.
[65]Sereda MW, Griffiths I, Puhlhofer A, et al. A transgenic rat model of Charcot-Marie-Tooth disease. Neuron,1996,16(5):1049-1060.
[66]Suter U, Welcher AA, Ozcelik T, et al. Trembler mouse carries a point mutation in a myelin gene. Nature,1992,356(6366):241-244.
[67]Huxley C, Passage E, Manson A, et al. Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. Hum Mol Genet,1996,5(5):563-569.
[68]Huxley C, Passage E, Robertson AM, et al. Correlation between varying levels of PMP22 expression and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice. Hum Mol Genet,1998,7(3):449-458.
[69]Magyar JP, Martini R, Ruelicke T, et al. Impaired differentiation of Schwann cells in transgenic mice with increased PMP22 gene dosage. J Neurosci,1996, 16(17):5351-5360.
[70]Robertson AM, Perea J, McGuigan A, et al. Comparison of a new pmp22 transgenic mouse line with other mouse models and human patients with CMT1A. J Anat,2002,200(4):377-390.
[71]Suter U, Moskow JJ, Welcher AA, et al. A leucine-to-proline mutation in the putative first transmembrane domain of the 22-kDa peripheral myelin protein in the trembler-J mouse. Proc Natl Acad Sci USA,1992,89(10):4382-4386.
[72]Suh JG, Ichihara N, Saigoh K, et al. An in-frame deletion in peripheral myelin protein-22 gene causes hypomyelination and cell death of the Schwann cells in the new Trembler mutant mice. Neuroscience,1997,79(3):735-744.
[73]Isaacs AM, Davies KE, Hunter AJ, et al. Identification of two new Pmp22 mouse mutants using large-scale mutagenesis and a novel rapid mapping strategy. Hum Mol Genet,2000,9(12):1865-1871.
[74]Adlkofer K, Martini R, Aguzzi A, et al. Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat Genet,1995,1(3):274-280.
[75]Adlkofer K, Frei R, Neuberg DH, et al. Heterozygous peripheral myelin protein 22-deficient mice are affected by a progressive demyelinating tomaculous neuropathy. J Neurosci,1997,17(12):4662-4671.
[76]Giese KP, Martini R, Lemke G, et al. Mouse P0 gene disruption leads to hypomyelination, abnormal expression of recognition molecules, and degeneration of myelin and axons. Cell,1992,71(4):565-576.
[77]Wrabetz L, Feltri ML, Quattrini A, et al. P(0) glycoprotein overexpression causes congenital hypomyelination of peripheral nerves. J Cell Biol, 2000,148(5):1021-1034.
[78]Runker AE, Kobsar I, Fink T, et al. Pathology of a mouse mutation in peripheral myelin protein P0 is characteristic of a severe and early onset form of human Charcot-Marie-Tooth type 1B disorder. J Cell Biol,2004,165(4):565-573.
[79]Wrabetz L, D'Antonio M, Pennuto M, et al. Different intracellular pathomechanisms produce diverse myelin protein zero neuropathies in transgenic mice. J Neurosci,2006,26(8):2358-2368.
[80]Anzini P, Neuberg DH, Schachner M, et al. Structural abnormalities and deficient maintenance of peripheral nerve myelin in mice lacking the gap junction protein connexin 32. J Neurosci,1997,17(12):4545-4551.
[81]Scherer SS, Bone LJ, Deschenes SM, et al. The role of the gap junction protein connexin32 in the pathogenesis of X-linked Charcot-Marie-Tooth disease. Novartis Found Symp,1999,219:175-185.
[82]Schneider-Maunoury S, Topilko P, Seitandou T, et al. Disruption of Krox-20 results in alteration of rhombomeres 3 and 5 in the developing hindbrain. Cell, 1993,75(6):1199-1214.
[83]Nagarajan R, Le N, Mahoney H, et al. Deciphering peripheral nerve myelination by using Schwann cell expression profiling. Proc Natl Acad Sci USA,2002, 99(13):8998-9003.
[84]Gillespie CS, Sherman DL, Fleetwood-Walker SM, et al. Peripheral demyelination and neuropathic pain behavior in periaxin-deficient mice. Neuron, 2000,26(2):523-531.
[85]Bolino A, Bolis A, Previtali SC, et al. Disruption of Mtmr2 produces CMT4B1-like neuropathy with myelin outfolding and impaired spermatogenesis. J Cell Biol,2004,167(4):711-721.
[86]Bonneick S, Boentert M, Berger P, et al. An animal model for Charcot-Marie-Tooth disease type 4B1. Hum Mol Genet,2005,14(23):3685-3695.
[87]Zhao C, Takita J, Tanaka Y, et al. Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta. Cell,2001,105(5):587-597.
[88]Lee MK, Marszalek JR, Cleveland DW. A mutant neurofilament subunit causes massive, selective motor neuron death:implications for the pathogenesis of human motor neuron disease. Neuron,1994,13(4):975-988.
[89]De Sandre-Giovannoli A, Chaouch M, Kozlov S, et al. Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse. Am J Hum Genet,2002,70(3):726-736.
[90]Miyazaki J, Takaki S, Araki K, et al. Expression vector system based on the chicken beta-actin promoter directs efficient production of interleukin-5.Gene. 1989,79(2):269-277.
[91]Sereda MW, Meyer zu Horste G, Suter U, et al. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med,2003,9(12):1533-1537.
[92]Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med,2004,10(4):396-401.
[93]Kappe G, Franck E, Verschuure P, et al. The human genome encodes 10 alpha-crystallin-related small heat shock proteins:HspB1-10. Cell Stress Chaperones.2003,8(1):53-61.
[94]Zhu Q, Couillard-Despres S, Julien JP. Delayed maturation of regenerating myelinated axons in mice lacking neurofilaments. Exp Neurol,1997, 148:299-316.
[95]Wilhelmus MM, Boelens WC, Otte-Holler I,et al. Small heat shock protein HSPB8:its distribution in Alzheimer's disease brains and its inhibition of amyloid-beta protein aggregation and cerebrovascular amyloid-beta toxicity. Acta Neuropathol.2006,111 (2):139-149.
[96]Outeiro TF, Klucken J, Strathearn KE, et al. Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. Biochem Biophys Res Commun.2006,351(3):631-638.
[97]Zourlidou A, Gidalevitz T, Kristiansen M, et al. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease:chronic neurodegeneration does not induce Hsp27 activation. Hum Mol Genet.2007,16(9):1078-1090.
[98]Sharp PS, Akbar MT, Bouri S, et al. Protective effects of heat shock protein 27 in a model of ALS occur in the early stages of disease progression. Neurobiol Dis.2008,30(1):42-55.
[99]Wang J, Martin E. Gonzales V, et al. Differential regulation of small heat shock proteins in transgenic mouse models of neurodegenerative diseases. Neurobiol Aging.2008,29(4):586-597.
[1]Raeymaekers P, Immerman V, De Jonghe P, et al. Localization of the mutation in an extended family with Charcot-Marie-Tooth neuropathy (HMSN I). Am J Hum Genet,1989,45(6):953-958.
[2]Boerkoel CF, Takashima H, Stankiewicz P, et al. Periaxin mutations cause recessive Dejerine-Sottas neuropathy. Am J Hum Genet,2001,68(2):325-333.
[3]Suter U, Moskow JJ, Welcher AA, et al. A leucine-to-proline mutation in the putative first transmembrane domain of the 22-kDa peripheral myelin protein in the trembler-J mouse. Proc Natl Acad Sci USA,1992,89(10):4382-4386.
[4]Matsunami N, Smith B, Ballard L, et al. Peripheral myelin protein-22 gene maps in the duplication in chromosome 17p11.2 associated with Charcot-Marie-Tooth 1A. Nat Genet,1992,1(3):176-179.
[5]Sereda MW, Griffiths I, Puhlhofer A, et al. A transgenic rat model of Charcot-Marie-Tooth disease. Neuron,1996,16(5):1049-1060.
[6]Sereda MW, Meyer zu Horste G, Suter U, et al. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med,2003,9(12):1533-1537.
[7]Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med,2004,10(4):396-401.
[8]Huxley C, Passage E, Manson A, et al. Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. Hum Mol Genet,1996,5(5):563-569.
[9]Podratz JL, Rodriguez E, Windebank AJ. Role of the extracellular matrix in myelination of peripheral nerve. Glia,2001,35(1):35-40.
[10]Podratz JL, Rodriguez EH, Windebank AJ. Antioxidants are necessary for myelination of dorsal root ganglion neurons, in vitro. Glia,2004,45(1):54-58.。
[11]Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med,2004,10(4):396-401.
[12]Robertson A, Huxley C. Transgenic models of inherited neuropathy. In:Dyck PJ, Thomas PK, editors. Peripheral neuropathy.4th ed. vol.2. Amsterdam:Elsevier Saunders; 2005. pp.1561-1583.A careful review of animal models of inherited neuropathies caused by mutations in myelin proteins.
[13]Wrabetz L, Feltri ML, Suter U. Models of Charcot-Marie-Tooth disease. In:Lazzarini RA, editor. Myelin biology and disorders. Vol.2. Amsterdam:Elsevier Academy; 2004. pp.1143-1168.
[14]Huxley C, Passage E, Robertson AM, et al. Correlation between varying levels of PMP22 expression and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice. Hum Mol Genet,1998,7(3):449-458.
[15]Niemann S, Sereda MW, Suter U, et al. Uncoupling of myelin assembly and Schwann cell differentiation by transgenic overexpression of peripheral myelin protein 22. J Neurosci,2000,20(11):4120-4128.
[16]Robaglia-Schlupp A, Pizant J, Norreel JC, et al. PMP22 overexpression causes dysmyelination in mice. Brain,2002,125(10):2213-2221.
[17]Sereda MW, Meyer zu Horste G, Suter U, et al. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med,2003,9(12):1533-1537.
[18]Adlkofer K, Martini R, Aguzzi A, et al. Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat Genet,1995, 1(3):274-280.